AstraZeneca's Ultomiris Showed Zero Relapses In Patients With Chronic Disorder Of Brain, Spinal Cord

• AstraZeneca Plc (NASDAQ: AZN) posted detailed results from the Phase 3 CHAMPION-NMOSD trial of Ultomiris (ravulizumab) For neuromyelitis optica spectrum disorder (NMOSD).

• NMOSD is an autoimmune disease that affects the central nervous system (CNS), including the spine and optic nerves.

• The data showed that Ultomiris significantly reduced relapse risk in adults with anti-aquaporin-4 (AQP4) antibody-positive (Ab+) NMOSD, compared to the external placebo arm from the pivotal Soliris PREVENT clinical trial.

• Data showed zero adjudicated relapses were observed among Ultomiris patients with a median treatment duration of 73 weeks (relapse risk reduction: 98.6%). Additionally, 100% of patients receiving Ultomiris remained relapse-free at 48 weeks, compared to 63% of patients in the external placebo arm.

• The CHAMPION-NMOSD trial also met key secondary efficacy endpoints, including adjudicated on-trial annualized relapse rate and clinically important change from baseline in the ability to walk.

• Price Action: AZN shares are down 0.20% at $57.85 on the last check Thursday.

See more from Benzinga

• Intel's Self-Driving Tech Firm Raises Over $800M In IPO, Alphabet Misses Q3 Earnings Expectations, Lyft Cuts Price For Monthly Subscription Plan: Top Stories Wednesday, Oct. 26

• AstraZeneca Touts Positive Data From Two Experimental Drugs In Breast Cancer Settings

• Garry Kasparov Says Rishi Sunak's First Phone Call As UK PM Was To 'The Leader Of The Free World' — It Wa

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.